The solid dosage form segment accounted for the largest share of the market in 2014. However, mu-opioid receptor antagonist was the fastest growing segment due to https://www.toiletstool.net/ recent launch of the new drug Moventik and presence of pipeline drugs (naldemedine and other early stage drugs). This is due to high patient compliance and launch of new drugs in solid form such as capsules, tablets, and pills. Drug classes include mu-opioid receptor antagonist, chloride channel activator, and others based on their mechanism of action. Asia Pacific, Latin America, and Middle East & Africa are the major consumers of traditional medicines used to treat opioid induced constipation due to easy access, low cost, and less awareness about targeted therapy.
The segment is expected to maintain its leadership position during the forecast period.Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. Linaclotide is another potential drug, which is currently in phase II clinical trial.Furthermore, based on dosage form, the market has been segmented into solid, semi-solid, and liquid. Acquisitions and collaborations among major companies to commercialize OIC medicines are expected to boost the market during the forecast period.The report provides detailed analysis of current and emerging drugs for opioid induced constipation treatment, and the market is estimated based on type of drug class and dosage form of the drugs.
The others segment includes Resolor (prucalopride), bulking agents (cellulose and psyllium), stool softeners (docusate), laxatives, and osmotic agents (lactulose, sorbitol.However, monthly cost of Amitiza ranges from US 300 to US 400 and from US 600 to US 1000 for Relistor. Traditional laxatives are not legally approved for the treatment of opioid induced constipation. The chloride channel activator segment accounted for the largest share of the opioid induced constipation treatment market in 2014 due to first approval and launch of Amitiza in major countries.In addition, in October 2014, Takeda and Sucampo entered into global license, development, and commercialization agreement for Amitiza. Presently, Amitiza is the only available drug that belongs to the chloride channel activator class. The number of players operating in the opioid induced constipation treatment market is small, while demand for the therapy is high.
The segment is expected to maintain its leadership position during the forecast period.Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. Linaclotide is another potential drug, which is currently in phase II clinical trial.Furthermore, based on dosage form, the market has been segmented into solid, semi-solid, and liquid. Acquisitions and collaborations among major companies to commercialize OIC medicines are expected to boost the market during the forecast period.The report provides detailed analysis of current and emerging drugs for opioid induced constipation treatment, and the market is estimated based on type of drug class and dosage form of the drugs.
The others segment includes Resolor (prucalopride), bulking agents (cellulose and psyllium), stool softeners (docusate), laxatives, and osmotic agents (lactulose, sorbitol.However, monthly cost of Amitiza ranges from US 300 to US 400 and from US 600 to US 1000 for Relistor. Traditional laxatives are not legally approved for the treatment of opioid induced constipation. The chloride channel activator segment accounted for the largest share of the opioid induced constipation treatment market in 2014 due to first approval and launch of Amitiza in major countries.In addition, in October 2014, Takeda and Sucampo entered into global license, development, and commercialization agreement for Amitiza. Presently, Amitiza is the only available drug that belongs to the chloride channel activator class. The number of players operating in the opioid induced constipation treatment market is small, while demand for the therapy is high.
コメント